Other News To Note
Wednesday, August 15, 2012
Arrowhead Research Corp., of Pasadena, Calif., said that it entered into an agreement with Merck & Co. Inc., through a subsidiary, to evaluate a novel therapeutic monoclonal antibody candidate derived from its human-derived peptide targeting and discovery program, which was acquired through the purchase of Alvos Therapeutics in April.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.